Although there are exciting new techniques to treat acute episodesof gastrointestinal bleeding, prevention is certainly preferable.In this issue of the Journal, Jensen and his colleagues presentevidence that long-term maintenance therapy with histamine H2-receptorantagonists significantly reduces the incidence of recurrentbleeding in patients who have previously bled from a duodenalulcer1. Prophylactic therapy has drawbacks, however, includingside effects and cost. Thus, there is increasing interest inidentifying patients who are at special risk for bleeding sothat the use of preventive therapy can be limited.
HINDS, C J, FLETCHER, S N
(1999). Ranitidine reduced clinically important gastrointestinal bleeding in patients who required mechanical ventilation • Commentary. Gut
44: 10-11
[Full Text]
Cook, D., Guyatt, G., Marshall, J., Leasa, D., Fuller, H., Hall, R., Peters, S., Rutledge, F., Griffith, L., McLellan, A., Wood, G., Kirby, A., Tweeddale, M., Pagliarello, J., Johnston, R., The Canadian Critical Care Trials Group,
(1998). A Comparison of Sucralfate and Ranitidine for the Prevention of Upper Gastrointestinal Bleeding in Patients Requiring Mechanical Ventilation. NEJM
338: 791-797
[Abstract][Full Text]
Bardes, C. L., Charlson, M. E., Martin, L. F., Shumate, M. J., Roberts, M. S., Cook, D. J., Guyatt, G. H., Griffith, L.
(1994). Gastrointestinal Bleeding in Critically Ill Patients. NEJM
331: 51-53
[Full Text]
Loffeld, R.J.L.F., van der Putten, A.B.M.M., Jensen, D. M., Peterson, W. L.
(1994). Ranitidine and Recurrent Hemorrhage from Duodenal Ulcer. NEJM
331: 53-54
[Full Text]